bioAffinity Technologies (NASDAQ:BIAF) is a biomedical company focused on developing and marketing non-invasive diagnostic tests and cancer therapeutics. The company's flagship project, CyPath® Lung, aims to revolutionize early lung cancer detection through a simple sputum test. bioAffinity Technologies is committed to improving patient outcomes by providing accurate, early-stage cancer detection options that can lead to more effective treatment and increased survival rates. Their objective is to extend diagnostic technologies across multiple types of cancer, emphasizing the importance of early detection in cancer care. Through innovative research and strategic partnerships, bioAffinity Technologies strives to make a significant impact in the fight against cancer.